Search Results 861-870 of 16073 for pharmacogenetics
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products ...
Chief Medical ResidentFamily Medicine Residency, Family Medicine, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of ...
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...
This study is designed to determine whether an oral perioperative medication (alvimopan--a selective mu antagonist) improves bowel recovery over placebo after ...
About this study. The purpose of this study is to assess age-dependent increases in Von Willebrand Factor (VWF) levels in patients with Type 1 Von ...
The purpose of this study is to determine how cystatin C, creatinine, and microalbuminuira change with gender affirming hormone therapy initiation. Blood draws ...
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, ...
See information about research education and training opportunities in Mayo Clinic's Department of Molecular Pharmacology and Experimental Therapeutics.
To determine the RP2D of MEN1611 when administered orally in combination with cetuximab to patients with PIK3CA mutated colorectal cancer failing irinotecan, ...
Pemigatinib is also used to treat myeloid/lymphoid neoplasms (blood cancer) that has come back or did not respond to treatment in patients who have a certain ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your GivingTuesday gift can go 2X as far.